Can we predict chemotherapy response in patients with metastatic testicular cancer? Role of thrombocytosis as a novel marker

GÖKCE M. İ., Mermerkaya M., SÜER E., Afandiyev F., Baltaci S.

MINERVA UROLOGICA E NEFROLOGICA, cilt.69, sa.4, ss.342-348, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 69 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.23736/s0393-2249.16.02690-4
  • Dergi Adı: MINERVA UROLOGICA E NEFROLOGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.342-348
  • Anahtar Kelimeler: Testicular neoplasms, Germ cell and embryonal neoplasms, Drug therapy, Thrombocytosis, GERM-CELL TUMORS, PREOPERATIVE THROMBOCYTOSIS, PROGNOSTIC-SIGNIFICANCE, CISPLATIN RESISTANCE, OVARIAN-CARCINOMA, COOPERATIVE GROUP, SURVIVAL, ETOPOSIDE, SEMINOMA
  • Ankara Üniversitesi Adresli: Evet

Özet

BACKGROUND: Primary treatment of choice for advanced germ cell tumors is 3 to 4 cycles of combination bleomycin-etoposide-cisplatin (BEP) chemotherapy. Although most patients treated for advanced germ cell tumors (GCT) will be cured, approximately 30% will fail to achieve a durable complete response (CR). Thrombocytosis has been found to be related with significantly shorter survival in many cancers. However, its role in testicular cancer patients has not been studied previously. The objective of this study was to investigate the relationship between thrombocytosis and chemotherapy response in patients with metastatic testicular cancer.